Turner et al. concluded that amplification and overexpression of FGFR1 may be a major contributor to poor prognosis in luminal-type breast cancers, driving anchorage-independent proliferation and endocrine therapy resistance[15]. The gene discussed is FGFR1; the disease is breast carcinoma.